Ardent Health (NYSE:ARDT) Price Target Cut to $11.00 by Analysts at JPMorgan Chase & Co.

Ardent Health (NYSE:ARDT) had its price objective trimmed by JPMorgan Chase & Co. from $12.00 to $11.00 in a research report released on Tuesday morning,Benzinga reports. The firm currently has a neutral rating on the stock.

Several other analysts have also recently commented on ARDT. Bank of America decreased their price target on shares of Ardent Health from $12.00 to $10.00 and set an “underperform” rating for the company in a report on Thursday, November 13th. Leerink Partners set a $16.00 price target on shares of Ardent Health in a research note on Friday, November 14th. KeyCorp lowered Ardent Health from an “overweight” rating to a “sector weight” rating in a research report on Monday, November 17th. Morgan Stanley reaffirmed an “equal weight” rating and set a $12.00 price target (down from $22.00) on shares of Ardent Health in a research note on Friday, November 14th. Finally, The Goldman Sachs Group began coverage on Ardent Health in a report on Tuesday, October 14th. They set a “neutral” rating and a $19.00 price target for the company. Six equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $14.58.

Ardent Health Price Performance

NYSE:ARDT opened at $8.28 on Tuesday. The company has a quick ratio of 1.95, a current ratio of 2.08 and a debt-to-equity ratio of 0.67. The business’s 50-day moving average price is $8.96 and its 200 day moving average price is $11.65. Ardent Health has a 52-week low of $8.22 and a 52-week high of $15.65. The firm has a market cap of $1.19 billion, a P/E ratio of 5.71, a PEG ratio of 4.91 and a beta of 0.72.

Ardent Health (NYSE:ARDT) last posted its quarterly earnings data on Wednesday, November 12th. The company reported $0.52 earnings per share for the quarter, beating the consensus estimate of $0.42 by $0.10. The company had revenue of $1.58 billion during the quarter, compared to analyst estimates of $1.55 billion. Ardent Health had a net margin of 3.24% and a return on equity of 19.02%. Ardent Health has set its FY 2025 guidance at 0.850-1.030 EPS. As a group, sell-side analysts predict that Ardent Health will post 1.23 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in ARDT. Goldman Sachs Group Inc. boosted its position in Ardent Health by 1,684.9% during the first quarter. Goldman Sachs Group Inc. now owns 767,862 shares of the company’s stock worth $10,558,000 after purchasing an additional 724,841 shares during the period. Ameriprise Financial Inc. raised its position in shares of Ardent Health by 75.6% in the second quarter. Ameriprise Financial Inc. now owns 1,634,822 shares of the company’s stock valued at $22,332,000 after purchasing an additional 703,739 shares during the period. SageView Advisory Group LLC lifted its stake in shares of Ardent Health by 367.2% in the second quarter. SageView Advisory Group LLC now owns 790,663 shares of the company’s stock worth $10,800,000 after buying an additional 621,430 shares during the last quarter. Hotchkis & Wiley Capital Management LLC bought a new stake in shares of Ardent Health during the 3rd quarter worth $6,377,000. Finally, Bridgeway Capital Management LLC bought a new stake in shares of Ardent Health during the 3rd quarter worth $6,024,000.

Trending Headlines about Ardent Health

Here are the key news stories impacting Ardent Health this week:

• Positive Sentiment: Independent bullish analysis highlighting a value/bull case for ARDT that some investors may view as upside support. Ardent Health, Inc. (ARDT): A Bull Case Theory
• Neutral Sentiment: JPMorgan trimmed its price target to $11.00 from $12.00 and maintained a “neutral” rating — a modest downgrade that reduces near-term analyst support but still implies upside from current levels. Read More
• Neutral Sentiment: Consensus broker recommendations sit around “Hold,” suggesting mixed analyst sentiment and limited near-term positive catalyst from upgrades. Ardent Health, Inc. (NYSE:ARDT) Given Consensus Recommendation of “Hold” by Brokerages
• Negative Sentiment: Multiple law firms have filed or announced securities class actions after a sharp prior share decline; plaintiffs allege misleading disclosures that could lead to litigation costs, settlements, or damages. (Lead-plaintiff deadline: March 9, 2026.) STOCK ALERT: Ardent Health, Inc. (ARDT) Stock Plummets 33% Triggering Securities Fraud Class Action by BFA Law, Contact the Firm before March 9 Deadline
• Negative Sentiment: Hagens Berman and other firms allege Ardent misled investors about revenue recognition systems and the adequacy of professional liability reserves — specific allegations that can materially increase downside risk if proven. ARDT INVESTOR NOTICE: Ardent Health, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
• Negative Sentiment: Numerous law firms (Rosen, Wolf Haldenstein, Pomerantz, Faruqi, etc.) are soliciting lead-plaintiff roles and reminding investors of the March 9 deadline, keeping the story in active press flow and maintaining selling pressure. Shareholders who lost money in shares of Ardent, Inc. (NYSE: ARDT) Should Contact Wolf Haldenstein Immediately

Ardent Health Company Profile

Ardent Health, listed on the New York Stock Exchange under the ticker ARDT, is a healthcare delivery company focused on acquiring, developing and managing acute care hospitals and complementary outpatient facilities across the United States. The company’s integrated platform encompasses both inpatient and outpatient services, designed to provide end-to-end care solutions and address the full continuum of patient needs.

Through its network, Ardent Health operates general hospitals, emergency departments, ambulatory surgery centers, urgent care clinics, rehabilitation and post-acute care facilities.